Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Bms 907351
2. Bms-907351
3. Bms907351
4. Cabozantinib
5. Cometriq
6. Xl 184
7. Xl-184
8. Xl184 Cpd
1. 1140909-48-3
2. Cabozantinib Malate
3. Cabozantinib (s)-malate
4. Cabometyx
5. Cabozantinib Malate (xl184)
6. Xl184
7. Cabozantinib (s-malate)
8. Cometriq
9. Cabozantinib S-malate [usan]
10. Dr7st46x58
11. Bms907351
12. Chebi:72319
13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
14. Cabometyx (tn)
15. Cometriq (tn)
16. Cabozantinib Malate (jan)
17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid
18. Cabozantinib S-malate (usan)
19. Cabozantinib Malate [jan]
20. Unii-dr7st46x58
21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
23. Xl184 Malate
24. Cabozantinib L-malate
25. Bms907351 Malate
26. Xl184(cabozantinib Malate)
27. Mls006010951
28. Chembl2103868
29. Dtxsid60915949
30. Ex-a2819
31. Mfcd20923480
32. S4001
33. 1140909-48-3 (malate)
34. Akos025401945
35. Cabozantinib S-malate [who-dd]
36. Ccg-270301
37. Cs-0201
38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor
39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
40. Ac-27471
41. As-75255
42. Hy-12044
43. Smr004702755
44. Cabozantinib S-malate [orange Book]
45. Sw218093-2
46. D10095
47. Q27139901
48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)
52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt
53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)
54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate
| Molecular Weight | 635.6 g/mol |
|---|---|
| Molecular Formula | C32H30FN3O10 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 11 |
| Exact Mass | 635.19152232 g/mol |
| Monoisotopic Mass | 635.19152232 g/mol |
| Topological Polar Surface Area | 194 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 924 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
* Renal Cell Carcinoma (RCC):
Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):
- in treatment-nave adults with intermediate or poor risk,
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
* Hepatocellular Carcinoma (HCC):
Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
L01EX07
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38207
Submission : 2023-03-31
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm :
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pamirae Co., Ltd.
Registration Date : 2025-04-04
Registration Number : Su574-29-ND
Manufacturer Name : Dr.Reddy's Laboratories Limited
Manufacturer Address : CTO-SEZ Process Unit-01 Sector No’s. 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survey No's. 57 to 58, 60, 72 to 73, 76 to 77 & 80, Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District-532409, Andhra Pradesh, India
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39274
Submission : 2023-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39757
Submission : 2024-03-22
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39785
Submission : 2024-03-26
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2019-12-17
Pay. Date : 2019-10-11
DMF Number : 34201
Submission : 2019-11-06
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39141
Submission : 2023-12-01
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38207
Submission : 2023-03-31
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39274
Submission : 2023-12-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-12-06
Pay. Date : 2023-03-08
DMF Number : 38057
Submission : 2023-09-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-06-25
Pay. Date : 2019-04-22
DMF Number : 33137
Submission : 2018-09-01
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-06-08
Pay. Date : 2017-05-22
DMF Number : 31522
Submission : 2017-03-30
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2022-03-23
Pay. Date : 2022-02-28
DMF Number : 36509
Submission : 2022-02-28
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39785
Submission : 2024-03-26
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39757
Submission : 2024-03-22
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-12-17
Pay. Date : 2019-10-11
DMF Number : 34201
Submission : 2019-11-06
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm : Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District -532409, Andhr...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-07-28
Valid Till : 2025-11-30
Written Confirmation Number : WC-0390
Address of the Firm : Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District -532409, Andhr...
Date of Issue : 2025-12-03
Valid Till : 2028-04-14
Written Confirmation Number : WC-0340
Address of the Firm : R.S No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Va...

Date of Issue : 2022-09-30
Valid Till : 2025-04-14
Written Confirmation Number : WC-340n
Address of the Firm : RS No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Vad...

Date of Issue : 2025-09-19
Valid Till : 2028-05-05
Written Confirmation Number : WC-0349
Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Pamirae Co., Ltd.
Registration Date : 2025-04-04
Registration Number : Su574-29-ND
Manufacturer Name : Dr.Reddy's Laboratories Limi...
Manufacturer Address : CTO-SEZ Process Unit-01 Sector No’s. 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survey ...
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-05-19
Registration Number : Su434-54-ND
Manufacturer Name : MSN Laboratories Private Lim...
Manufacturer Address : Unit-II, Sy. No. 50, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Te...

Registrant Name : Ipsen Korea Co., Ltd.
Registration Date : 2019-04-26
Registration Number : Su183-2-ND
Manufacturer Name : Piramal Healthcare Canada Lt...
Manufacturer Address : 110 Industrial Parkway North Aurora, Ontario, Canada, L4G 3H4

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-059
Start Marketing Date : 2023-03-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 72804-0003
Start Marketing Date : 2024-12-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 54893-0130
Start Marketing Date : 2025-06-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 54893-0512
Start Marketing Date : 2024-09-30
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 54893-0058
Start Marketing Date : 2017-02-06
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 55679-116
Start Marketing Date : 2012-11-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 83137-0002
Start Marketing Date : 2023-02-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59057-013
Start Marketing Date : 2022-08-31
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 59057-019
Start Marketing Date : 2024-09-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 64918-1924
Start Marketing Date : 2023-05-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
About the Company : Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-growth therapeutic ar...
About the Company : Sichuan Qingmu Pharmaceutical is an innovation-driven company specializing in generic APIs, advanced intermediates, and CDMO/CMO services for small-molecule drugs. Approved by US F...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

About the Company : Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is de...

About the Company : The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are Ind...

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

About the Company : We are a world class innovation driven specialty pharmaceutical company with integrated Research, Development, Manufacturing and Marketing of Quality affordable medicines for a Hea...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Belzutifan is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of von hippel-lindau disease.
Lead Product(s): Belzutifan,Palbociclib,Nivolumab,Lenvatinib,Cabozantinib
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Belzutifan,Palbociclib,Nivolumab,Lenvatinib,Cabozantinib
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Details : Belzutifan is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of von hippel-lindau disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Pumitamig,Ipilimumab,Cabozantinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: BioNTech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pumitamig,Ipilimumab,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : BioNTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The proceeds from the offering will be used to fund the clinical development of Casdatifan, a small molecule product targeting HIF-2α in the key focus area of cancer.
Lead Product(s): Casdatifan,Cabozantinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Leerink Partners | Goldman Sachs & Co | Cantor | Mizuho | Truist Securities
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Casdatifan,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leerink Partners | Goldman Sachs & Co | Cantor | Mizuho | Truist Securities
Deal Size : $250.0 million
Deal Type : Public Offering
Arcus Biosciences Prices $250M Public Offering of Common Stock
Details : The proceeds from the offering will be used to fund the clinical development of Casdatifan, a small molecule product targeting HIF-2α in the key focus area of cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The proceeds from the offering will be used to fund the clinical development of Casdatifan, a miscellaneous product targeting HIF-2-alpha in the key focus area of cancer.
Lead Product(s): Casdatifan,Cabozantinib
Therapeutic Area: Oncology Brand Name: AB521
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Leerink Partners | Goldman Sachs & Co
Deal Size: $234.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Casdatifan,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leerink Partners | Goldman Sachs & Co
Deal Size : $234.5 million
Deal Type : Public Offering
Arcus Biosciences Begins Public Offering of Common Stock
Details : The proceeds from the offering will be used to fund the clinical development of Casdatifan, a miscellaneous product targeting HIF-2-alpha in the key focus area of cancer.
Product Name : AB521
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration aims to advance Casdatifan for HIF-2α targeting in clear cell renal cell carcinoma.
Lead Product(s): Casdatifan,Cabozantinib
Therapeutic Area: Oncology Brand Name: AB521
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Taiho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Casdatifan,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Taiho Pharma Licenses Casdatifan in Japan and Asia Territories
Details : The collaboration aims to advance Casdatifan for HIF-2α targeting in clear cell renal cell carcinoma.
Product Name : AB521
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 19, 2025

Details:
Cabozantinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Cabozantinib,Nivolumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Exelixis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2025

Lead Product(s) : Cabozantinib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabozantinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Casdatifan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Casdatifan,Cabozantinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Casdatifan,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Casdatifan + Cabozantinib Vs. Placebo + Cabozantinib In RCC
Details : Casdatifan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Neoplasms.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Gustave Roussy
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nivolumab,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Gustave Roussy
Deal Size : Inapplicable
Deal Type : Inapplicable
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cabozantinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Exelixis Wins U.S. FDA Nod for CABOMETYX in Advanced Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Product Name : Cabometyx
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Abemaciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Lead Product(s): Abemaciclib,Cabozantinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Eli Lilly | Exelixis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abemaciclib,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Eli Lilly | Exelixis
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Details : Abemaciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2025

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]4-Chloro-6,7-dimethoxyquinoline
CAS Number : 35654-56-9
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
1-((4-Fluoro phenyl) Carbamoyl) Cyclopropane Carbo...
CAS Number : 849217-48-7
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
4-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline
CAS Number : 190728-25-7
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
Cyclopropane-1,1-dicarboxylic acid methyl ester
CAS Number : 113020-21-6
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
1,1-Cyclopropanedicarboxylic acid
CAS Number : 598-10-7
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
4-CHLORO-6,7-DIMETHOXYQUINOLINE
CAS Number : 35654-56-9
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CYCLOPROPANE-1,1-DICARBOXYLIC ACID
CAS Number : 598-10-7
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

1-((4-FLUOROPHENYL)CARBAMOYL)CYCLOPROPANE-1- CARBO...
CAS Number : 849217-48-7
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

4-((6,7-DIMETHOXY-QUINOLIN-4-YL)OXY)ANILINE
CAS Number : 190728-25-7
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

4-chloro-6,7-dimethoxyquinoline
CAS Number : 35654-56-9
End Use API : Cabozantinib
About The Company : We are into manufacturing of bulk drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is contract manufacturing for our clients ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Cabometyx
Dosage Form : Film Coated Tablet
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Not Marketed
Registration Country : Norway
Brand Name : Cometriq
Dosage Form : Capsule
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Not Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Cometriq
Dosage Form : Capsule
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Estonia
Brand Name : Cabometyx
Dosage Form : Film-Coated Tablet
Dosage Strength : 60mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Estonia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Cabometyx
Dosage Form : Film Coated Tablet
Dosage Strength : 40MG
Packaging :
Approval Date : 05-12-2016
Application Number : 1161136004
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Cabometyx
Dosage Form : Film Coated Tablet
Dosage Strength : 20MG
Packaging :
Approval Date : 05-12-2016
Application Number : 1161136002
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Cometriq
Dosage Form : Hard Capsules
Dosage Strength : 20mg; 80mg
Packaging :
Approval Date : 21-03-2014
Application Number : 28105211812
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Cometriq
Dosage Form : Capsule
Dosage Strength : 20mg, 80mg
Packaging :
Approval Date : 21-03-2014
Application Number : 2.01E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Cabozantinib \"Teva\"
Dosage Form : Film Coated Tablet
Dosage Strength : 20mg
Packaging :
Approval Date : 24-06-2025
Application Number : 28106942223
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Cabozantinib \"Teva\"
Dosage Form : Film Coated Tablet
Dosage Strength : 60mg
Packaging :
Approval Date : 24-06-2025
Application Number : 28106942423
Regulatory Info : Prescription
Registration Country : Denmark

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2030-10-08
US Patent Number : 8877776
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208692
Patent Use Code : U-3225
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-10-08

Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-3225
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-01-15

Patent Expiration Date : 2032-02-10
US Patent Number : 12128039
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208692
Patent Use Code : U-2488
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-02-10

Patent Expiration Date : 2032-02-10
US Patent Number : 12128039
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208692
Patent Use Code : U-2488
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-02-10

Patent Expiration Date : 2026-08-14
US Patent Number : 7579473
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208692
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2026-08-14

Patent Expiration Date : 2030-01-15
US Patent Number : 11091439
Drug Substance Claim : Y
Drug Product Claim :
Application Number : 208692
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-01-15

Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-2488
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-01-15

Patent Expiration Date : 2030-01-15
US Patent Number : 11098015
Drug Substance Claim :
Drug Product Claim :
Application Number : 208692
Patent Use Code : U-1480
Delist Requested :
Patent Use Description : TREATMENT OF ADVANCED ...
Patent Expiration Date : 2030-01-15

Patent Expiration Date : 2030-10-08
US Patent Number : 8877776
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 203756
Patent Use Code : U-1617
Delist Requested :
Patent Use Description : METHOD OF TREATING MED...
Patent Expiration Date : 2030-10-08

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
82
PharmaCompass offers a list of Cabozantinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabozantinib manufacturer or Cabozantinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabozantinib manufacturer or Cabozantinib supplier.
PharmaCompass also assists you with knowing the Cabozantinib API Price utilized in the formulation of products. Cabozantinib API Price is not always fixed or binding as the Cabozantinib Price is obtained through a variety of data sources. The Cabozantinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cabozantinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib, including repackagers and relabelers. The FDA regulates Cabozantinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabozantinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabozantinib supplier is an individual or a company that provides Cabozantinib active pharmaceutical ingredient (API) or Cabozantinib finished formulations upon request. The Cabozantinib suppliers may include Cabozantinib API manufacturers, exporters, distributors and traders.
click here to find a list of Cabozantinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cabozantinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib DMFs exist exist since differing nations have different regulations, such as Cabozantinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cabozantinib DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib USDMF includes data on Cabozantinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cabozantinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cabozantinib Drug Master File in Korea (Cabozantinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib. The MFDS reviews the Cabozantinib KDMF as part of the drug registration process and uses the information provided in the Cabozantinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cabozantinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cabozantinib suppliers with KDMF on PharmaCompass.
A Cabozantinib written confirmation (Cabozantinib WC) is an official document issued by a regulatory agency to a Cabozantinib manufacturer, verifying that the manufacturing facility of a Cabozantinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib APIs or Cabozantinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Cabozantinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabozantinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabozantinib suppliers with NDC on PharmaCompass.
Cabozantinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cabozantinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib GMP manufacturer or Cabozantinib GMP API supplier for your needs.
A Cabozantinib CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib's compliance with Cabozantinib specifications and serves as a tool for batch-level quality control.
Cabozantinib CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cabozantinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib EP), Cabozantinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib USP).